Cargando…
Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189954/ https://www.ncbi.nlm.nih.gov/pubmed/33914268 http://dx.doi.org/10.1007/s12325-021-01694-x |
| _version_ | 1783705590648799232 |
|---|---|
| author | Finck, Barbara Geller, Robert B. Walden, Paul |
| author_facet | Finck, Barbara Geller, Robert B. Walden, Paul |
| author_sort | Finck, Barbara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8189954 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81899542021-06-28 Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” Finck, Barbara Geller, Robert B. Walden, Paul Adv Ther Letter Springer Healthcare 2021-04-29 2021 /pmc/articles/PMC8189954/ /pubmed/33914268 http://dx.doi.org/10.1007/s12325-021-01694-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Finck, Barbara Geller, Robert B. Walden, Paul Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title | Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title_full | Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title_fullStr | Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title_full_unstemmed | Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title_short | Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” |
| title_sort | letter to the editor regarding “the challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence” |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189954/ https://www.ncbi.nlm.nih.gov/pubmed/33914268 http://dx.doi.org/10.1007/s12325-021-01694-x |
| work_keys_str_mv | AT finckbarbara lettertotheeditorregardingthechallengesofswitchingtherapiesinanevolvingmultiplebiosimilarslandscapeanarrativereviewofcurrentevidence AT gellerrobertb lettertotheeditorregardingthechallengesofswitchingtherapiesinanevolvingmultiplebiosimilarslandscapeanarrativereviewofcurrentevidence AT waldenpaul lettertotheeditorregardingthechallengesofswitchingtherapiesinanevolvingmultiplebiosimilarslandscapeanarrativereviewofcurrentevidence |